Viking Therapeutics (VKTX) EPS (Weighted Average and Diluted): 2017-2025
Historic EPS (Weighted Average and Diluted) for Viking Therapeutics (VKTX) over the last 5 years, with Sep 2025 value amounting to -$0.81.
- Viking Therapeutics' EPS (Weighted Average and Diluted) fell 268.18% to -$0.81 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.12, marking a year-over-year decrease of 127.96%. This contributed to the annual value of -$1.01 for FY2024, which is 10.99% down from last year.
- As of Q3 2025, Viking Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.81, which was down 39.66% from -$0.58 recorded in Q2 2025.
- Viking Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at -$0.16 for Q4 2021, and its period low was -$0.81 during Q3 2025.
- In the last 3 years, Viking Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.25 in 2023 and averaged -$0.34.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first rose by 17.39% in 2023, then plummeted by 268.18% in 2025.
- Quarterly analysis of 5 years shows Viking Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.16 in 2021, then plummeted by 62.50% to -$0.26 in 2022, then climbed by 3.85% to -$0.25 in 2023, then fell by 28.00% to -$0.32 in 2024, then tumbled by 268.18% to -$0.81 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.81 in Q3 2025, compared to -$0.58 in Q2 2025 and -$0.41 in Q1 2025.